Imugene Ltd · ASX:IMU
Imugene — Shareholder Meeting (November 2024)
18 slides from Imugene's shareholder meeting presentation, Nov 14, 2024
Slide 1: Leading Innovation in Cancer Treatment
For personal use only Leading Innovation in Cancer Treatment AGM, November 2024 1 Release authorised by the Managing Director and Chief Executive Officer Imugene Limited
Slide 2: Disclaimer
Disclaimer The information in this presentation does not constitute personal investment Neither the Company nor any of its directors, officers, employees, advisers, advice. The presentation is not intended to be comprehensive or provide all associated persons or subsidiaries are liable for any direc
Slide 3: Imugene is a clinical stage cancer company
For personal use only Imugene is a clinical stage cancer company developing three drug products in CAR T cell therapy and oncolytic viruses. 3
Slide 4: Seasoned and Highly Engaged Board Of Directors
Seasoned and Highly Engaged Board Of Directors Diverse expertise, market sector leadership and catalysts for value creation For personal use only Paul Hopper Dr. Jakob Dupont, MD Leslie Chong Kim Drapkin Dr. Lesley Russell Dr. Jens Eckstein Executive Chairman Non-Executive Director CEO & Managing No
Slide 5: Experienced Leadership Team
Experienced Leadership Team has brought > 17 FDA Approved Drugs to Market For personal use only Leslie Chong Dr. Paul Woodard, MD Dr. Bradley Glover, PhD Ursula McCurry Dr. John Byon, MD, PhD Dr. Monil Shah Chief Executive Officer Chief Medical Officer MBA Chief Clinical Senior VP of Clinical Head o
Slide 6: Investment Highlights
Investment Highlights Market Capitalisation A$342M Cash Position A$54.3M (Pro-forma) As of 13 November 2024 As of 30 September 2024 For personal use only 4 PLATFORM DISEASE AREAS LONG- TECHNOLOGIES Blood cancers LIFE Breast (TNBC) Lung (NSCLC) PATENT Gastric PORTFOLIO Gastroesophageal Colorectal (CR
Slide 7: Three Novel Cancer Technologies In Clinical Trials
Three Novel Cancer Technologies In Clinical Trials For personal use only CF33 Oncolytic Virus onCARlytics CD19 targeting virus azer-cel CD19 CAR T VAXINIA MAST Trial OASIS Trial Phase 1b Phase 1 Phase 1 Novel virus which acts as a CD19 target in Off-the-shelf drug, aka “Allo”geneic Novel cancer kill
Slide 8: What is Autologous CAR T Therapy?
What is Autologous CAR T Therapy? A cancer treatment in which a patient’s T-cells are reprogramed in a laboratory so that they become like a guided missile to attack certain proteins (ie CD19) on the cancer cells − CAR T stands for chimeric antigen receptor T-cell. Currently many CD19 targeted auto
Slide 9: What is Imugene's azer-cel Allogeneic CAR T?
What is Imugene’s azer-cel Allogeneic CAR T? Azer-cel is an Azer-cel is currently Approximately ‘off-the-shelf’ enrolling patients with a 30,000 CAR T drug, rare form of blood cancer cases (US) per For personal use only aka allogeneic, which is made known as diffuse large B year of DLBCL from health
Slide 10: 67% Complete Response Rates Observed in Phase 1b Cohort B
67% Complete Response Rates Observed in Phase 1b Cohort B Evaluable patients: Evaluable Evaluable Cohort A+B patients: patients: (N=9) Cohort A (N=6) Cohort B (N=3) For personal use only Cohort A Overall 6 Response Rate % 4 (44%) 2 (33%) 2 (67%) Patients Complete 3 (33%) 1 (17%) 2 (67%) Lymphodeplet
Slide 11: Representative PET Scans Of Complete Responses
Representative PET Scans Of Complete Responses Subject Treatment Summary For personal use only • 47 yo female, first diagnosed with High-grade B- Tumour-free cell lymphoma (HGBCL), stage IV in Jul 2022. Tumour Treated at Emory University. • Prior to azer-cel, patient failed 4 prior lines of therapy;
Slide 12: CF33 VAXINIA Can Infect and Kill Cancer Cells
CF33 VAXINIA Can Infect and Kill Cancer Cells 1 2 3 For personal use only Virus enters Virus Cell explodes, releasing tumour cell duplicates thousands of brand new itself virus particles Engineering enhancements Multiple ways to kill cancer cells Precedent for approval • Infect and kill only cancer
Slide 13: Phase MAST Trial − Encouraging Early Signals
Phase 1 MAST Trial − Encouraging Early Signals Patients1 • >40 patients have been dosed and evaluated (at least their first scan at day 42) For personal use only Disease Control So Far • Nearly half of the evaluable patients (48%) have remained on treatment for >3 months • 3 patients have remained o
Slide 14: What is Imugene's onCARlytics CD19 virus?
What is Imugene’s onCARlytics CD19 virus? Imugene’s novel onCARlytics CD19 virus, makes a solid cancer “resemble” a CD19 blood cancer cell, and lures FDA approved anti-CD19 CAR T drugs, to attack them For personal use only Solid cancers do not have the CD19 IMU’s CD19 virus causes solid cancers This
Slide 15: 2024 Highlights
2024 Highlights azer-cel: Three Complete Responses in azer-cel Phase 1B DLBCL trial For personal use only azer-cel: First Australian site open for Phase 1b Clinical Trial VAXINIA: Positive early trial update; 1 CR (in remission for over 2 years), 2 PRs, All treatments determined to be safe and toler
Slide 16: Expected Upcoming Key Catalysts H2 2024/2025
Expected Upcoming Key Catalysts H2 2024/2025 • azer-cel: DLBCL Phase 1b interim data update For personal use only • azer-cel: Target regulatory meeting with FDA • azer-cel: FPI in Phase 2 study • azer-cel: Expansion into additional blood cancers (Phase 1b Expansion Cohort) • onCARlytics: IT and/or I
Slide 17: Imugene Commercialisation Strategy
Imugene Commercialisation Strategy Multiple Value Realisation Pathways For personal use only Due to the network effect, each financial advisor represents hundreds of potential COMPANY They often manage more PARTNER WITH These investors BIG have the They makeLICENSE decisions quickly DEVELOP / shareh
Slide 18: For personal use only
ASX : IMU For personal use only shareholderenquiries@imugene.com imugene.com 18